

QP Code: 104521

Reg. No:

**M.Ch (Gynaecological Oncology) Degree Regular/Supplementary
Examinations November 2023**

Paper IV – Recent Advances in Gynaecologic Oncology

Time: 3 hrs

Max marks: 100

- *Answer all questions to the point neatly and legibly • Do not leave any blank pages between answers • Indicate the question number correctly for the answer in the margin space*
- *Answer all parts of a single question together • Leave sufficient space between answers*
- *Draw table/diagrams/flow charts wherever necessary*

Essay:

(20)

1. What is Poly (ADP-Ribose) Polymerase. What role does PARP play in cancer recurrence. Discuss the role of PARP inhibitors in the treatment of epithelial ovarian cancer. (4+6+10)

Short essays:

(8x10=80)

2. Discuss the role of sentinel node biopsy in vulval cancer.
3. Justify the role of ovarian cancer screening among women who has a strong family history of breast and ovarian cancer.
4. Is self-sampling for HPV test appropriate for population screening for cervical cancer. Justify.
5. How was PORTEC-3 trial designed. How did it change the adjuvant treatment policy for endometrial cancer. (4+6)
6. High grade serous ovarian cancer originates at the fimbrial end of the fallopian tube. Discuss.
7. What is the current evidence of menopausal hormone therapy for young women who had undergone hysterectomy and bilateral salpingo-oophorectomy for endometrial cancer.
8. Under which circumstances will you use bevacizumab in the treatment of ovarian cancer. Justify your answer with reference to the literature.
9. What are immune check-point inhibitors. Discuss the role of immunotherapy in the treatment of endometrial cancer. (4+6)
